Melissa Helena Rodrigues Silva, Joaquim Fechine de Alencar Neto, Otávio da Cunha Ferreira Neto, Luis Bandeira Alves Neto, Nilson Batista Lemos, Arthur Oliveira Lira, M. L. Rocha, Luís Felipe Ferreira Marques, Victor Egypto Pereira, Victoria Rodrigues Durand, Ana Cristina Veiga Silva, Luiz Severo Bem Júnior, Hildo Rocha Cirne de Azevedo Filho
{"title":"Impacts of the preempt protocol on chronic migraine: an integrative review","authors":"Melissa Helena Rodrigues Silva, Joaquim Fechine de Alencar Neto, Otávio da Cunha Ferreira Neto, Luis Bandeira Alves Neto, Nilson Batista Lemos, Arthur Oliveira Lira, M. L. Rocha, Luís Felipe Ferreira Marques, Victor Egypto Pereira, Victoria Rodrigues Durand, Ana Cristina Veiga Silva, Luiz Severo Bem Júnior, Hildo Rocha Cirne de Azevedo Filho","doi":"10.48208/headachemed.2022.18","DOIUrl":null,"url":null,"abstract":"Chronic migraine is an important cause of functional disability and quality of life deficits, affecting 12% of the world population. Therefore, more treatment alternatives that promote better pain control are needed. So, botulinum toxin type A presents itself as a therapeutic option for this purpose. This integrative review aimed to analyze the functionality of the PREEMPT protocol applied for the treatment of chronic migraine, analyzing the time of pain control, the frequency of repetition of the treatment and the possible subtypes of pain that benefit most from botulinum toxin. Data were collected from the National Library of Medicine and Lilacs databases, and the research concluded in July 2022. 31 articles were found, of which only 22 publications were considered eligible to compose this study, and those that contemplated the research objectives were selected. above. Botulinum toxin type A presents an effective, safe and well-tolerated preventive profile for patients with chronic migraine, increasing the patient's quality of life and works in pain control.","PeriodicalId":12925,"journal":{"name":"Headache Medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Headache Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48208/headachemed.2022.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic migraine is an important cause of functional disability and quality of life deficits, affecting 12% of the world population. Therefore, more treatment alternatives that promote better pain control are needed. So, botulinum toxin type A presents itself as a therapeutic option for this purpose. This integrative review aimed to analyze the functionality of the PREEMPT protocol applied for the treatment of chronic migraine, analyzing the time of pain control, the frequency of repetition of the treatment and the possible subtypes of pain that benefit most from botulinum toxin. Data were collected from the National Library of Medicine and Lilacs databases, and the research concluded in July 2022. 31 articles were found, of which only 22 publications were considered eligible to compose this study, and those that contemplated the research objectives were selected. above. Botulinum toxin type A presents an effective, safe and well-tolerated preventive profile for patients with chronic migraine, increasing the patient's quality of life and works in pain control.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
